Background We compared standard adjuvant anthracycline chemotherapy with
anthracycline–taxane combination chemotherapy in women with operable node-positive …

PURPOSE The incidence of cardiometabolic risk factors in breast cancer (BC) survivors has
not been well described. Thus, we compared risk of hypertension, diabetes, and …

Purpose Most women diagnosed with breast cancer are younger than 65 years of age.
Population-based studies on cancer therapy–related cardiotoxicity have focused on older …

Cardiovascular toxicity is a potential complication of cancer chemotherapy (CC) that
increases the morbidity and mortality of cancer patients. Cardiac arrhythmias have been …

Purpose Approximately 35% of HER2-amplified breast cancers have coamplification of the
topoisomerase II-alpha (TOP2A) gene encoding an enzyme that is a major target of …

More women are living with and surviving breast cancer, because of improvements in breast
cancer care. Trastuzumab (Herceptin®▾) has significantly improved outcomes for women …

Background Current recommendations that cancer patients receive a maximum cumulative
dose of 900 mg/m2 epirubicin are based on the risk of epirubicin-mediated cardiotoxicity …

Doxorubicin (DOX) is used for treating various cancers. Its clinical use is, however, limited by
its dose-limiting cardiomyopathy. The exact mechanism of DOX-induced cardiomyopathy …

Background Combined anthracycline-trastuzumab chemotherapy has been associated with
LV dysfunction. We aimed to assess early changes in left ventricular (LV) and right …

As an anthracycline antibiotic, doxorubicin (DOX) is one of the most potent and widely used
chemotherapeutic agents for treating various types of tumors. Unfortunately, the clinical …